All In Biotech

Free tool

FAERS Monitor: Kanjinti

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761073 or its brand name (Kanjinti, Trastuzumab-Anns). Reports on generic versions are filed under their own applications.

Reports

1,514

Serious

365

24% of reports

Hospitalization

111

Death reported

25

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product storage error346
  • circumstance or information capable of leading to medication error257
  • off label use115
  • intercepted product administration error89
  • product dose omission issue69
  • diarrhoea64
  • dyspnoea62
  • chills58
  • nausea54
  • fatigue51
  • rash49
  • intercepted product preparation error42
  • accidental exposure to product40
  • product preparation error40
  • infusion related reaction36

Reports by year received

View as table
YearReports
20161
201972
2020217
2021206
2022248
2023364
2024278
202575
202653

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,645 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intercepted product administration errorSignal89163.1133.214,021
circumstance or information capable of leading to medication errorSignal257106.595.226,595
product storage errorSignal34655.150.218,336
intercepted product preparation errorSignal4247.635.31,863
product preparation errorSignal4027.120.0979
infusion related reactionSignal367.55.5199
chillsSignal586.95.3287
accidental exposure to productSignal405.44.0139
product dose omission issueSignal693.32.6107
off label use1151.81.544
rash491.61.210
dyspnoea621.51.211
diarrhoea641.41.16
nausea540.90.70
fatigue510.90.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.